Aspirin Therapy Guidelines for Patients with Coronary Stents

Formulation Preference

Non‑enteric‑coated aspirin (chewable or regular tablets) should be prescribed for patients with coronary stents, avoiding enteric‑coated (time‑delayed) formulations because they provide delayed and reduced absorption that jeopardizes antiplatelet efficacy. 1
Non‑enteric‑coated aspirin achieves more rapid buccal absorption, delivering reliable and predictable platelet inhibition compared with enteric‑coated preparations. 2
The 2014 American Heart Association/American College of Cardiology (AHA/ACC) guideline explicitly recommends non‑enteric‑coated aspirin (162–325 mg loading dose) for acute coronary syndromes, a principle that extends to chronic maintenance where consistent absorption is critical. Class I recommendation. 1

The recommended maintenance dose is aspirin 81 mg taken once daily and should be continued indefinitely after stent placement. 1, 3
An 81 mg daily dose provides cardiovascular protection equivalent to higher doses (162–325 mg) while markedly lowering the risk of bleeding complications. 1
High‑dose aspirin (≥160 mg) is linked to increased bleeding without any improvement in clinical outcomes for patients receiving dual antiplatelet therapy. 1

Prescribe either chewable 81 mg aspirin or regular (non‑enteric‑coated) 81 mg tablets once daily. 1, 2
Chewable formulations ensure buccal absorption and may be advantageous when a rapid antiplatelet effect is desired, though either chewable or regular non‑enteric‑coated tablets are acceptable for routine maintenance. 2
Do not prescribe “enteric‑coated,” “delayed‑release,” or “safety‑coated” aspirin formulations for any patient with a coronary stent. 1

Aspirin therapy must be maintained indefinitely in all patients with coronary stents, irrespective of stent type (bare‑metal or drug‑eluting). 3
When a P2Y12 inhibitor (e.g., clopidogrel, ticagrelor, prasugrel) is also used, the aspirin dose should remain at 81 mg daily to minimize bleeding risk while preserving dual antiplatelet efficacy. 1, 3

Avoid prescribing enteric‑coated aspirin under the assumption that it reduces gastrointestinal side effects; the resulting delayed absorption compromises antiplatelet effectiveness. 1
Higher maintenance doses such as 325 mg should not be used in the chronic setting because they increase bleeding risk without delivering additional cardiovascular benefit. 1

The American Heart Association recommends that aspirin should be continued indefinitely as a Class I recommendation (highest level of evidence) after percutaneous coronary intervention (PCI) with stent placement 4, 5
Low-dose aspirin (81 mg daily) is preferred over higher maintenance doses due to lower bleeding risk while maintaining efficacy, as recommended by the American College of Cardiology 6, 7, 8
Continued treatment with aspirin after PCI reduces major adverse cardiac events (MACE), according to the American Heart Association 6, 9

For elderly patients, the 81 mg daily dose is particularly appropriate as it balances antithrombotic benefits with lower bleeding risk, as suggested by the American College of Cardiology 7, 8
Higher maintenance doses of aspirin (>100 mg) increase bleeding complications without providing additional reduction in cardiovascular events, according to the American Heart Association 8

Aspirin therapy should be continued indefinitely after stent placement, regardless of the type of stent (bare-metal or drug-eluting), as recommended by the American College of Cardiology 9, 4
This recommendation applies to all patients with coronary stents, including elderly patients, according to the American Heart Association 6, 5

In addition to aspirin, a P2Y12 inhibitor (such as clopidogrel) is typically recommended for at least 12 months after drug-eluting stent placement, as suggested by the American College of Cardiology 9, 4
For bare-metal stents, P2Y12 inhibitors are recommended for a minimum of 1 month and ideally up to 12 months, according to the American Heart Association 4, 5

For elderly patients with increased bleeding risk, the benefit of aspirin therapy still outweighs the risks in those with prior stent placement, as recommended by the American College of Cardiology 8
If bleeding risk is a concern, using the lowest effective dose (81 mg) and considering proton pump inhibitor therapy for gastrointestinal protection may be appropriate, according to the American Heart Association 6, 9